Hemostatic rescue with rFVIIa in Bernard–Soulier syndrome refractory to HLA-matched platelet transfusion
Authors:
Open Access
- 26 February 2026
- journal article
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (4)
Abstract
We report the case of a man in his 50’s diagnosed with Bernard-Soulier syndrome (BSS) in childhood who developed refractory gluteal bleeding following a fall accident. The patient underwent four hematoma evacuation procedures and multiple platelet transfusions, including HLA (human leukocyte antigen) -matched platelet concentrates, without achieving sustained hemostatic control. Given the lack of response to platelet transfusion and ongoing bleeding risk, Eptacog Alfa (recombinant activated factor VII; rFVIIa) was administered for 4 days, following the dosing regimen recommended for Glanzmann thrombasthenia in surgical bleeding settings. Hemostasis was achieved shortly after rFVIIa administration, and no further surgical evacuation was necessary. Importantly, no thromboembolic complications occurred despite the use of rFVIIa. This case demonstrates that rFVIIa can serve as an effective adjunctive hemostatic therapy in patients with BSS who are refractory to platelet transfusions. We reviewed the existing literature on rFVIIa use in patients with BSS and summarized the clinical contexts, dosing strategies, efficacy, and safety outcomes. Our experience suggests that early consideration of rFVIIa may help prevent repeated surgical interventions and reduce bleeding-related morbidity in complex cases.Keywords
All Related Versions
Funding Information
- FY2025 Kyoto University Hospital Research Fund for Young Scientists
This publication has 16 references indexed in Scilit:
- Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard–Soulier syndromeHaemophilia, 2009
- Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard–Soulier syndromeThrombosis Research, 2007
- The Evidence for the Use of Recombinant Human Activated Factor VII in the Treatment of Bleeding Patients With Quantitative and Qualitative Platelet DisordersTransfusion Medicine Reviews, 2007
- Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard–Soulier syndromeAnnals of Hematology, 2005
- Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet countJournal of Thrombosis and Haemostasis, 2005
- CASE REPORT: Severe Recurrent Gastrointestinal Bleeding Due to Angiodysplasia in a Bernard–Soulier Patient: An Onerous Medical ConcomitanceDigestive Diseases and Sciences, 2004
- The use of recombinant factor VIIa in children with inherited platelet function disordersBritish Journal of Haematology, 2003
- The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe ThrombocytopathiaSeminars in Thrombosis and Hemostasis, 2000
- A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitorsHaemophilia, 1998
- Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.1998